12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Istodax romidepsin regulatory update

Celgene submitted an sNDA to FDA for Istodax romidepsin to treat peripheral T cell lymphoma (PTCL) in patients who have received >=1 prior therapy. The...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >